74 results about "Hematological malignancy" patented technology

The invention provides a hematologic tumor cord blood transplantation treatment prognosis index evaluation decision generation method and system based on prediction modeling, a medium and electronic equipment, and relates to the technical field of medical artificial intelligence. The method comprises the following steps: acquiring multi-source data of a key time point in a whole process of blood tumor umbilical cord blood transplantation treatment of a patient; integrating expert knowledge to form an expert knowledge network, taking the expert knowledge network as priori knowledge of multi-target prediction, and performing multi-dimensional prognosis prediction by using multi-source data; periodically acquiring time sequence multi-source data, capturing time evolution characteristics of patient states, and automatically triggering an updating mechanism at a key clinical time point to dynamically adjust a prediction result; generating a risk assessment grade, a feature importance analysis result and an individualized interpretation report based on the prediction result, and performing visualization; and generating a clinical decision using the large language model. According to the technology, accurate evaluation and individualized clinical decision support for hematologic tumor cord blood transplantation prognosis are achieved.

The invention discloses a CD7 and FAS double-gene knockout CD7 CAR-T cell and a preparation method and application thereof.By means of the method, the self-killing phenomenon of the CAR-T cell can be avoided, the cell amplification efficiency and the treatment effect can be improved, in addition, the survival ability and durability of the CAR-T cell can be remarkably enhanced, the method has remarkable advantages in treatment of T cell hematological malignancies, and the method is suitable for being used for treating T cell hematological malignancies. The method has a good application prospect and important conversion significance.

Methods and systems for detecting cancer and / or determining a cancer tissue of origin are disclosed. In some embodiments, a multiclass cancer classifier is disclosed that is trained with a plurality of biological samples containing cfDNA fragments. The analytics system derives a feature vector for each sample, and the multiclass classifier predicts a probability likelihood for each of a plurality of tissue of origin (TOO) classes. In some embodiments, the plurality of TOO classes include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples having high tissue signal are pruned from the training sample set. In another embodiment, the analytics system stratifies samples according to tissue signal and applies binary threshold cutoffs determined for each stratum.

Described herein are LAG3 specific single domain antibodies and binding molecules comprising such single domain antibodies, as well as nucleic acids encoding the same. Also provided are nucleic acids (e.g., mRNA) encoding such single domain antibodies and binding molecules and delivery vehicles (e.g., lipid nanoparticles) formulated with said nucleic acids. The disclosure also features methods of using such antibodies, binding molecules, nucleic acids, and delivery vehicles formulated with said nucleic acids to treat various diseases such as inflammatory diseases, T cell driven autoimmune diseases, and cancer (e.g., solid tumors or hematological malignancies).

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

This invention discloses a class of 2-(2-(quinolin-4-yloxy)ethyl)pyridazine-3(2H)-one compounds, their preparation methods, and applications. The structure of these compounds is shown in general formula (I). This invention also discloses that the above compounds have a significant inhibitory effect on interleukin-1 receptor-associated kinase 1 (IRAK1). These compounds can inhibit the proliferation of various tumor cells, including liver cancer, lung cancer, pancreatic cancer, gastric cancer, kidney cancer, colon cancer, esophageal cancer, glioblastoma, leukemia, multiple myeloma, and other solid tumors and hematological malignancies. This invention provides a new option for tumor treatment.

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The present invention relates to treating malignancies such as tumors or cancers by orally administering lyophilized compositions comprising arsenic to a subject in such need. Malignancies include various hematological malignancies, such as acute myeloid leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), multiple myeloma (MM) and lymphomas and solid tumors including glioblastoma multiforme and breast cancer. This invention relates to a novel formulation comprising a lyophilized compositions comprising arsenic. The present invention also relates to a method for lyophilizing the arsenic trioxide, preparing the oral formulation comprising lyophilized compositions comprising arsenic, and a method for treating a subject with malignancies using the oral formulation.

Described herein are methods of treating a hematological malignancy, including minimal residual disease in hematological malignancies, and methods of preventing relapse of hematological malignancies, the methods comprising administering an inflammasome modulator. In some embodiments the method of treatment comprises administering a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein the variables are as defined herein.

The present disclosure relates to antibodies and antibody fragments specific for CCR2. As reactivity with marmoset CCR2, which is a species that is crucial to further preclinical and clinical development, is lost, almost all attempts to humanize the original antibody are notified as failure. The antibodies are useful in the treatment of inflammatory diseases, autoimmune diseases, hematological malignancies, and potentially other diseases.

The present disclosure discloses methods and systems for detecting cancer and / or determining tissue of origin of cancer. In some embodiments, a multi-classification cancer classifier is disclosed that is trained using a plurality of biological samples containing cfDNA fragments. The analysis system derives a feature vector for each sample, and the multi-classification classifier predicts a probabilistic likelihood for each of a plurality of cancer signal origin (CSO) classifications. In some embodiments, the plurality of CSO classifications include hematological subtypes, including both hematological malignancies and precursor conditions. In one embodiment, non-cancer samples with high predictive scores are rejected from a training sample set. In another embodiment, the analysis system stratifies the sample according to a predicted score and applies a binary threshold cutoff value determined for each stratification.

The invention discloses a fused ring compound as well as a preparation method and application thereof. The fused ring compound has an excellent treatment effect on solid tumors such as gastric cancer, breast cancer, lung cancer or urothelial cancer or malignant tumors of a blood system.

The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Provided herein are formulations, processes, solid forms and methods of use (e.g., methods of treating a hematological malignancy) relating to salts of and solid forms comprising free base or salts of (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione.

To provide anti-Gal3 antibodies and methods of use.SOLUTION: Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Gal3 and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of antibodies or binding fragments thereof for treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.SELECTED DRAWING: Figure 1

The present invention relates to methods of treatment of light chain amyloidosis and other CD38-positive hematological malignancies with anti-CD38 antibodies.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

The present invention relates to a combination product comprising a Bcl-2 / Bcl-xL inhibitor and a chemotherapeutic agent, in particular a Bcl-2 / Bcl-xL inhibitor of formula I-A and homoharringtonine or an active derivative thereof, in free or pharmaceutically acceptable salt or solvate form. The invention also relates to the use of the aforementioned combination for the preparation of a medicament for the prevention and / or treatment of cancer, in particular of hematological malignancies, and to a method for the prevention and / or treatment of cancer, in particular of hematological malignancies, using the aforementioned combination.

To provide formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof.SOLUTION: Formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent, and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa s, and the pH of the solution is 5.9-7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations are useful in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.SELECTED DRAWING: None

This application relates to an anti-ROR1 antibody, an antibody-drug conjugate containing the antibody, a pharmaceutical composition and medical product containing the antibody-drug conjugate, and a method for producing and using the antibody-drug conjugate, wherein the antibody-drug conjugate is effective in treating and / or preventing ROR1-positive tumors, including hematological malignancies and solid tumors (e.g., cancers such as breast cancer and bladder cancer).

Methods of expanding peripheral blood lymphocytes (PBLs) from blood of patients with hematological malignancies, including lymphomas and leukemias, genetic modifications of expanded PBLs to incorporate chimeric antigen receptors, genetically modified T cell receptors, and other genetic modifications, and uses of such expanded and / or modified PBLs in the treatment of diseases such as cancers and hematological malignancies are disclosed herein.

Provided herein are compounds and isolated enantiomers useful for inhibiting telomerase, pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising at least one such compound, isolated enantiomer, or pharmaceutically acceptable salt thereof. Also described is the use of such compounds, isolated enantiomers, or pharmaceutically acceptable salts thereof, and the use of pharmaceutical compositions comprising at least one such compound, isolated enantiomer, or pharmaceutically acceptable salt thereof, in methods of treating disorders or conditions such as cancer, where the cancer may be a hematological malignancy or a solid tumor.

The present invention discloses a clinical data analysis method and system for hematological tumor patients based on knowledge graphs, which relates to the field of medical information processing technology. The present invention utilizes a natural language processing model to parse unstructured text and construct a standardized entity set. Laboratory indicators are aggregated through dynamic windows to construct a timeline data set annotated with treatment stages. Standardized entities are integrated based on a hematological tumor ontology model, and a dynamic global knowledge graph is constructed in combination with clinical causal relationships and temporal paths to achieve chain reaction warnings. Based on real-time patient subgraphs, successful cases with the same molecular characteristics are retrieved in the knowledge graph to generate a set of candidate treatment plans, and a graph neural network trained with an optimized algorithm is used to predict the risk of complications of each plan, and finally the optimal treatment plan is evaluated and selected. The present invention breaks through the barriers of clinical data, realizes dynamic reasoning, advanced risk warning and personalized plan optimization throughout the treatment cycle, and significantly improves the accuracy, safety and efficiency of medical resource utilization in diagnosis and treatment.

A PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of hematological malignancies in a subject, wherein the treatment comprises separate, sequential, or concurrent administration to the subject of i) the PI3K-delta inhibitor or a pharmaceutically acceptable salt thereof, and ii) a BCL-2 inhibitor or a pharmaceutically acceptable salt thereof. The treatment may also further comprise iii) separate, sequential, or concurrent administration to the subject of iii) further chemotherapeutic agents.

Provided are methods for treating CD33-positive hematological malignancies, such as acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), harboring mutations such as FLT3, IDH1, IDH2, NMP1, and / or MLL1 gene mutations, using combination therapy that includes one or both of a radiolabeled CD33-targeting agent and a drug-conjugated CD33-targeting agent, and one or more targeted therapies, such as FLT3, IDH and Menin inhibitors.

The present invention belongs to the field of biomedicine technology, and specifically relates to a method and application for culturing organoids of hematological malignancies. The culturing method of the present invention comprises: S01: obtaining a tumor cell sample; S02: preparing a bone marrow microenvironment-simulating matrix and resuspending the tumor cells; S03: adding a specific culture medium to culture hematological malignant tumor organoids; S04: phenotypic identification of the cultured hematological malignant tumor organoids; and screening out hematological malignant tumor organoids that are close to the patient's bone marrow cell phenotype. The method system of the present invention not only successfully cultured hematological malignant tumor organoids, but also further performed phenotypic identification on them. The screened hematological malignant tumor organoids are close to the patient's cell immune phenotype and can be used for accurate detection of clinical patient drug sensitivity and effective testing of potentially effective target drugs.

To provide compositions and methods for treatment of hematological tumors with engineered or non-engineered γδ-T cells.SOLUTION: In some embodiments, γδ-T cells comprise a chimeric antigen receptor (CAR) construct. The CAR construct can contain an anti-CD20 binding domain or anti-B cell maturation antigen (BCMA) binding domain, a CD8 hinge and transmembrane domain, a costimulatory domain, a CD3ζ signalling domain, a combination thereof, or all thereof. The CAR construct can contain a domain encoding for a secreted common gamma chain cytokine such as an sIL15 domain.SELECTED DRAWING: None

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

The invention discloses a polysubstituted amine compound, a pharmaceutical composition containing the polysubstituted amine compound and an application of the polysubstituted amine compound in tumor resistance. The structure of the polysubstituted amine compound is shown as a formula I in the specification. Through multiple experiments, the inventor of the invention proves that the compound disclosed by the invention has a remarkable inhibiting effect on FBXO44, and can be combined with the FBXO44 in cells to inhibit down-regulation of the FBXO44 on MTSS1, so that the formation of tumor cell microfilament skeletons is disturbed, and the compound has a strong anti-proliferation effect on gastric cancer cell strains such as NUGC4 and the like. Therefore, the compound disclosed by the invention can be used as an FBXO44 inhibitor to be applied to medicines for treating solid tumors or leukemia related to human or animal cell proliferation.